Oncimmune Signs Big Contract with Leading Global Drug Company

Oncimmune, a company specializing in autoantibody profiling to support precision medicine in the pharmaceutical and biotech sectors, has secured a new contract with a leading global pharmaceutical firm. This follows a successful pilot project conducted for the same client. The new agreement, valued at a minimum of $1.5 million, involves profiling Immunoglobulin E autoantibodies in blood serum and represents a significant expansion of their collaboration.

In the pilot phase, Oncimmune showcased its capability to accurately profile Immunoglobulin E (IgE) autoantibodies in blood serum through its advanced high-throughput bead-based technology. The upcoming project, set to unfold over the next six months, is anticipated to generate most of its revenue in fiscal year 2025.

Martin Gouldstone, CEO of Oncimmune remarked, “I am delighted that our scientific team has demonstrated our ability to measure IgE, which is much harder to detect in blood serum than other immunoglobulins, using our high-throughput platform.”

Oncimmune is a leader in precision medicine, focusing on immune system interactions by analyzing autoantibody profiles. By leveraging a platform-based strategy, Oncimmune collaborates with international pharmaceutical and biotech firms, alongside contract research organizations (CROs), to identify new biomarkers. This approach aims to advance the creation of targeted and effective treatments for various immune-mediated diseases. The company is based in the UK, with its research and development operations situated in Dortmund, Germany.